Project Grant R00HL171911
Award Date 8/1/26
Completion Date 6/30/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Scottsdale, AZ 85259, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic Arizona $1,665,204 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how P2RX7-expressing CD4+ T cells control virus-induced lung sequelae. The research defines how severe respiratory infections such as influenza and SARS-CoV-2 promote pathogenic lung CD4+ T cell accumulation that perpetuates long-term lung damage, including the irreversible organ dysfunction observed in long COVID...
- The National Heart, Lung, and Blood Institute awarded the Scripps Research Institute $1,101,338 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer noncovalent antibody-enzyme thrombolytic complexes that function orthogonally to the natural hemostatic system. The project, R01HL184492, addresses limitations of current plasminogen activator therapies—including narrow therapeutic window, contraindications, and risks of neurotoxicity, bleeding, and...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $820,111 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cell-specific role of the CD40L-CD40 co-stimulatory dyad in modulating atherosclerosis and natural antibody production. The project examines how CD40 expression on B1 cells—innate B cells that produce atheroprotective anti-oxidation-specific-epitope (OSE) immunoglobulin M—protects against atherosclerosis by...
- The National Heart, Lung, and Blood Institute awarded Emory University $391,211 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 1, 2026, to investigate alloimmune responses and anti-drug antibody formation against coagulation factor therapeutics in hemophilia patients. The research addresses inhibitor development—the formation of neutralizing antibodies against Factor VIII and Factor IX replacement therapies—which complicates treatment in approximately 30 percent of...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $593,663 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thrombolysis resistance in acute ischemic stroke with large vessel occlusion. The project addresses the failure of intravenous thrombolysis with tissue plasminogen activator (TPA) to achieve successful recanalization in most eligible patients. Mayo Clinic will conduct three integrated research activities: define metabolic...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $638,403 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the roles of group 2 innate lymphoid cells (ILC2s) in type 2 immunity and asthma. The project examines immunological mechanisms underlying airway inflammation in asthma patients, focusing on how ILC2s—which rapidly produce type 2 cytokines—regulate adaptive immune responses in the lungs and...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $209,765 on May 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate TIGIT+ B cell therapy as an immunosuppressive strategy to promote transplantation tolerance and suppress acute graft-versus-host disease. The research tests whether TIGIT+ B cells—generated using a novel replication-incompetent recombinant ADV5 vector (ADV5.K7.TIGIT)—can suppress...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $1,081,420 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic and translational research on platelet activation pathways and disorders of platelet count and function. The recipient will investigate cellular signaling pathways—particularly G proteins and integrin receptors—that control platelet adhesion and plug formation in hemostasis and...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $197,600 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to assess food-specific tolerogenic CD4+ T cells in protection from food allergy. The award funds research into the immunologic mechanisms that regulate food allergy development, with focus on understanding how oral exposure to food antigens protects against allergic sensitization and anaphylaxis compared to...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $149,214 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lipid-loaded macrophages in atherosclerotic plaque inflammation. The recipient will characterize the metabolic landscape and cell fate decisions of atheroma-derived macrophages under lipid loading, examining how lipid-associated macrophages release extracellular adenosine triphosphate as a pro-inflammatory signaling...